This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides FDA to Convene Pharmacy Compounding Advisory Committee in July Mark your calendar. July 23 24. FDA advisory committee reviewing BPC 157, TB 500, MOTS C, semax, epitalon, KPV, and DSIP for the 503A compounding list. The peptide landscape could shift significantly. Peptides are starting to move back into the conversation., After years of restriction under the FDAs 503A Category 2 list, were now seeing momentum toward re evaluation and potential reintroduction Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law